Cargando…
DRESS Syndrome and Daclizumab Failure—Were Potentially Dangerous Signs Missed in Clinical Trials?
The US Food and Drug Administration (FDA) approved Zinbryta, an interleukin-2 receptor blocking antibody (daclizumab; Biogen and AbbVie) for the treatment of adults with relapsing forms of multiple sclerosis (MS) in May, 2016. It was also approved by the European Union in July, 2016. Zinbryta is a l...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043933/ https://www.ncbi.nlm.nih.gov/pubmed/30013311 http://dx.doi.org/10.1177/1177392818785136 |